胸肌神经阻滞II对微创心脏手术患者的影响——一项前瞻性、随机、对照、三盲试验
该单中心、前瞻性、三盲、两组随机试验计划纳入60例择期单侧微创心脏手术患者,随机接受胸肌神经阻滞II(PECS II)与0.5%罗哌卡因30 ml(干预组)或0.9%氯化钠(安慰剂组)。主要结局为拔管后24小时内以静脉吗啡毫克当量(MME)表示的总阿片需求量;次要结局包括拔管后2、4、6、8、12、24小时视觉模拟量表(VAS)评分、24小时后总体镇痛获益评分(OBAS)、至拔管间隔、24小时内重症监护室(ICU)出院及住院时长(LOS)。
要点
- 单中心、前瞻性、三盲、两组随机试验,计划纳入60例择期单侧微创心脏手术患者。
- 干预组接受PECS II联合0.5%罗哌卡因30 ml,安慰剂组接受0.9%氯化钠。
- 主要结局为拔管后24小时内静脉吗啡毫克当量(MME)表示的总阿片需求量。
核心结论
- 该前瞻性随机对照三盲试验旨在评估PECS II联合0.5%罗哌卡因是否有助于减少微创心脏手术后24小时内的阿片需求量并改善术后疼痛控制。
研究设计与样本
- 单中心、前瞻性、三盲、两组随机对照试验,计划纳入60例择期单侧微创心脏手术患者。
主要发现
- 原文为试验方案,尚未报告结果。
关键数值与推荐
- 干预组PECS II使用0.5%罗哌卡因30 ml,安慰剂组使用0.9%氯化钠。
- 主要结局为拔管后24小时内以静脉吗啡毫克当量(MME)表示的总阿片需求量。
- 次要结局包括拔管后2、4、6、8、12、24小时VAS评分、24小时后OBAS、至拔管间隔、24小时内ICU出院及LOS。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Classic neuraxial techniques, such as thoracic epidural anesthesia, or alternative approaches like the paravertebral block, are not indicated in cardiac surgery due to increased bleeding risk. To provide satisfactory analgesia without the need for excessive opioid use, novel ultrasound techniques gained popularity and are of growing interest. The pectoralis nerve block II (PECS II) has been shown to provide good postoperative analgesia in modified radical mastectomy and might also be suitable for minimally invasive cardiac surgery. METHODS: In a single center, prospective, triple-blinded, two-group randomized trial, 60 patients undergoing elective, unilateral minimal invasive cardiac surgery will be randomized to receive a PECS II with 30 ml of ropivacaine 0.5% (intervention group) or sodium chloride 0.9% (placebo group). The primary outcome parameter is the overall opioid demand given as intravenous morphine milligram equivalents (MME) during the first 24 h after extubation. Secondary endpoints are the visual analog scale (VAS) 2, 4, 6, 8, 12, and 24 h after extubation, the Overall Benefit of Analgesia Score (OBAS) after 24 h, the interval until extubation, and intensive care unit (ICU) discharge within 24 h, as well as the length of hospital stay (LOS). DISCUSSION: This prospective randomized, controlled, and triple-blinded trial aims to assess if a PECS II with ropivacaine 0.5% helps to decrease the opioid demand in the first 24 h and increases postoperative pain control after minimally invasive cardiac surgery. TRIAL REGISTRATION: www.clinicaltrialsregister.eu ; EudraCT Nr: 2021-005452-11; Lukas Gasteiger MD, November 18, 2021.
引用
- Hoerner E, Stundner O, Naegele F, et al. The impact of PECS II blockade in patients undergoing minimally invasive cardiac surgery-a prospective, randomized, controlled, and triple-blinded trial. Trials. 2023. PMID: 37667362. doi:10.1186/s13063-023-07530-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。